Capsida Biotherapeutics

Capsida Biotherapeutics is a fully integrated gene therapy platform company focused on developing a new class of targeted, non-invasive gene therapies for rare and common diseases. Their innovative approach utilizes proprietary engineered adeno-associated virus (AAV) capsids, which enable high transduction levels to specific tissues and cells while limiting exposure to non-target organs, such as the liver. Their technology allows for intravenous (IV) delivery, making it less invasive than traditional methods and potentially opening up treatment possibilities for a broader range of diseases.

Capsida is driven by a commitment to unlock the full potential of gene therapy for all patients. They are currently focused on developing treatments for central nervous system (CNS) disorders, including genetic epilepsy and Parkinson’s disease. The company has established partnerships with AbbVie, Lilly, and CRISPR Therapeutics to accelerate the development of their promising therapies and expand their reach. This multi-functional company combines proprietary AAV engineering, multi-modality cargo development, translational biology, process development, and state-of-the-art manufacturing with broad clinical development expertise. Capsida's goal is to rapidly bring high-quality, life-changing therapies to patients suffering from debilitating diseases.

Capsida Biotherapeutics offers a comprehensive benefits package to its employees, including competitive health benefits such as medical, dental, vision and prescription drug coverage with multiple plan options including PPO, HMO, and HSA. The company also provides a competitive base salary with a bonus program, equity participation, life and disability insurance, and a 401k plan. Capsida also offers paid parental leave, competitive PTO, paid holidays including a summer and winter shutdown, employee resource groups, an employee assistance program, and on-site snacks.

Capsida Biotherapeutics is an industry-leading gene therapy platform company dedicated to developing a new class of targeted, non-invasive gene therapies for both rare and common diseases across all ages. The company's proprietary technology leverages engineered adeno-associated viruses (AAVs) to deliver gene therapies with superior cell and tissue targeting and safety profiles. Capsida's goal is to unlock the full potential of gene therapy by creating customized therapies that selectively target specific organ systems while simultaneously limiting exposure to non-targeted organs.

Capsida Biotherapeutics promotes a collaborative and innovative culture that values teamwork, curiosity, and execution. They foster a sense of collective responsibility and unity, encouraging employees to leverage their diverse backgrounds and thoughts to achieve common goals. The company is driven by a passion for improving patient lives and is committed to pushing the boundaries of gene therapy, remaining resilient in the face of adversity and blending innovation with execution to bring life-changing therapies to market.

Capsida Biotherapeutics is committed to building a diverse, equitable and inclusive workplace where all employees feel valued, respected, and empowered to contribute their unique perspectives and talents. They foster a culture of collaboration and innovation by embracing the power of diverse backgrounds, experiences, and perspectives. Capsida actively recruits and retains a workforce that reflects the diversity of the communities they serve and strives to create a welcoming and supportive environment where everyone can thrive.